BIOGEN INC (BIIB) Stock Fundamental Analysis
USA - NASDAQ:BIIB - US09062X1037 - Common Stock
143.74 USD
-1.13 (-0.78%)
Taking everything into account, BIIB scores 5 out of 10 in our fundamental rating. BIIB was compared to 540 industry peers in the Biotechnology industry. BIIB has an excellent profitability rating, but there are some minor concerns on its financial health. BIIB is cheap, but on the other hand it scores bad on growth. These ratings would make BIIB suitable for value investing!
1. Profitability
1.1 Basic Checks
In the past year BIIB was profitable.
In the past year BIIB had a positive cash flow from operations.
BIIB had positive earnings in each of the past 5 years.
Each year in the past 5 years BIIB had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 5.40%, BIIB belongs to the best of the industry, outperforming 91.48% of the companies in the same industry.
BIIB's Return On Equity of 8.68% is amongst the best of the industry. BIIB outperforms 92.59% of its industry peers.
BIIB has a better Return On Invested Capital (9.52%) than 94.07% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BIIB is significantly below the industry average of 15.95%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.4% | ||
| ROE | 8.68% | ||
| ROIC | 9.52% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
BIIB has a better Profit Margin (15.31%) than 93.70% of its industry peers.
BIIB's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 27.35%, BIIB belongs to the best of the industry, outperforming 96.30% of the companies in the same industry.
BIIB's Operating Margin has declined in the last couple of years.
BIIB's Gross Margin of 75.43% is amongst the best of the industry. BIIB outperforms 82.96% of its industry peers.
In the last couple of years the Gross Margin of BIIB has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.35% | ||
| PM (TTM) | 15.31% | ||
| GM | 75.43% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
BIIB has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
BIIB has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BIIB has been reduced compared to 5 years ago.
The debt/assets ratio for BIIB has been reduced compared to a year ago.
2.2 Solvency
BIIB has an Altman-Z score of 3.06. This indicates that BIIB is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.06, BIIB is doing good in the industry, outperforming 71.30% of the companies in the same industry.
BIIB has a debt to FCF ratio of 3.40. This is a good value and a sign of high solvency as BIIB would need 3.40 years to pay back of all of its debts.
BIIB has a Debt to FCF ratio of 3.40. This is amongst the best in the industry. BIIB outperforms 93.89% of its industry peers.
BIIB has a Debt/Equity ratio of 0.36. This is a healthy value indicating a solid balance between debt and equity.
BIIB has a Debt to Equity ratio of 0.36. This is in the lower half of the industry: BIIB underperforms 70.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | 3.4 | ||
| Altman-Z | 3.06 |
ROIC/WACC1.04
WACC9.2%
2.3 Liquidity
BIIB has a Current Ratio of 2.50. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
BIIB has a Current ratio of 2.50. This is in the lower half of the industry: BIIB underperforms 69.07% of its industry peers.
BIIB has a Quick Ratio of 1.79. This is a normal value and indicates that BIIB is financially healthy and should not expect problems in meeting its short term obligations.
BIIB has a Quick ratio of 1.79. This is in the lower half of the industry: BIIB underperforms 76.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.5 | ||
| Quick Ratio | 1.79 |
3. Growth
3.1 Past
BIIB shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.61%.
The earnings per share for BIIB have been decreasing by -13.31% on average. This is quite bad
Looking at the last year, BIIB shows a small growth in Revenue. The Revenue has grown by 3.36% in the last year.
BIIB shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.62% yearly.
EPS 1Y (TTM)-3.61%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%3.6%
Revenue 1Y (TTM)3.36%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%7.33%
3.2 Future
BIIB is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.26% yearly.
BIIB is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.33% yearly.
EPS Next Y-1.7%
EPS Next 2Y-1.08%
EPS Next 3Y0.58%
EPS Next 5Y1.26%
Revenue Next Year0.4%
Revenue Next 2Y-1.84%
Revenue Next 3Y-1.15%
Revenue Next 5Y-0.33%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 8.98, which indicates a very decent valuation of BIIB.
Based on the Price/Earnings ratio, BIIB is valued cheaper than 97.22% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.20. BIIB is valued rather cheaply when compared to this.
With a Price/Forward Earnings ratio of 8.92, the valuation of BIIB can be described as very reasonable.
BIIB's Price/Forward Earnings ratio is rather cheap when compared to the industry. BIIB is cheaper than 97.22% of the companies in the same industry.
BIIB's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.70.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.98 | ||
| Fwd PE | 8.92 |
4.2 Price Multiples
BIIB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BIIB is cheaper than 97.59% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, BIIB is valued cheaper than 97.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.41 | ||
| EV/EBITDA | 7.12 |
4.3 Compensation for Growth
The decent profitability rating of BIIB may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.08%
EPS Next 3Y0.58%
5. Dividend
5.1 Amount
No dividends for BIIB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:BIIB (9/18/2025, 3:56:03 PM)
143.74
-1.13 (-0.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.67%
Inst Owner Change-0.33%
Ins Owners0.14%
Ins Owner Change3.35%
Market Cap21.07B
Analysts72.86
Price Target172.46 (19.98%)
Short Float %3.23%
Short Ratio3.23
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.1%
Min EPS beat(2)17.28%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)15.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)13.06%
EPS beat(12)12
Avg EPS beat(12)11.49%
EPS beat(16)14
Avg EPS beat(16)10.96%
Revenue beat(2)2
Avg Revenue beat(2)9.15%
Min Revenue beat(2)6.67%
Max Revenue beat(2)11.62%
Revenue beat(4)3
Avg Revenue beat(4)4.43%
Min Revenue beat(4)-0.68%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)1.84%
Revenue beat(12)8
Avg Revenue beat(12)1.78%
Revenue beat(16)11
Avg Revenue beat(16)1.73%
PT rev (1m)-0.23%
PT rev (3m)-0.51%
EPS NQ rev (1m)0.07%
EPS NQ rev (3m)-3.55%
EPS NY rev (1m)6.04%
EPS NY rev (3m)5.87%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)2.72%
Revenue NY rev (1m)4.46%
Revenue NY rev (3m)4.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.98 | ||
| Fwd PE | 8.92 | ||
| P/S | 2.11 | ||
| P/FCF | 11.41 | ||
| P/OCF | 9.96 | ||
| P/B | 1.2 | ||
| P/tB | 12.59 | ||
| EV/EBITDA | 7.12 |
EPS(TTM)16.01
EY11.14%
EPS(NY)16.12
Fwd EY11.21%
FCF(TTM)12.6
FCFY8.76%
OCF(TTM)14.44
OCFY10.04%
SpS68.19
BVpS120.28
TBVpS11.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.4% | ||
| ROE | 8.68% | ||
| ROCE | 10.87% | ||
| ROIC | 9.52% | ||
| ROICexc | 10.7% | ||
| ROICexgc | 37.26% | ||
| OM | 27.35% | ||
| PM (TTM) | 15.31% | ||
| GM | 75.43% | ||
| FCFM | 18.47% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexcg growth 3Y14.15%
ROICexcg growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score6
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | 3.4 | ||
| Debt/EBITDA | 1.81 | ||
| Cap/Depr | 36.28% | ||
| Cap/Sales | 2.7% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 60.86% | ||
| Profit Quality | 120.66% | ||
| Current Ratio | 2.5 | ||
| Quick Ratio | 1.79 | ||
| Altman-Z | 3.06 |
F-Score6
WACC9.2%
ROIC/WACC1.04
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)-3.61%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%3.6%
EPS Next Y-1.7%
EPS Next 2Y-1.08%
EPS Next 3Y0.58%
EPS Next 5Y1.26%
Revenue 1Y (TTM)3.36%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%7.33%
Revenue Next Year0.4%
Revenue Next 2Y-1.84%
Revenue Next 3Y-1.15%
Revenue Next 5Y-0.33%
EBIT growth 1Y23.31%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year9.29%
EBIT Next 3Y4.38%
EBIT Next 5Y5.37%
FCF growth 1Y64.41%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y48.2%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%